Regen BioPharma

151 articles with Regen BioPharma

• Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023

  1/23/2023

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs,  will be presenting at the Emerging Growth Conference on January 25, 2023.

• Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio

  1/20/2023

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today the filing of a provisional patent application covering the use of survivin-engineered dendritic cells and exosomes for stimulation of anti-cancer immunity. 

• Regen BioPharma, Inc. to address 2023 goals and company direction at the Emerging Growth Conference on January 11, 2023

  1/9/2023

  Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.

• Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer

  12/19/2022

  Regen BioPharma, Inc. and As 2022 comes to a close, I would like to highlight some our many accomplishments achieved this year and also to respond to the multiple queries regarding future business strategy and planning that we have received.

• Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 14, 2022

  12/12/2022

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on December 14, 2022.

• Regen BioPharma Appoints Two New Scientific Advisory Board Members

  12/7/2022

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced that Dr. Ravinder Reddy, a Professor of Radiology at the University of Pennsylvania and Dr. Mohammad Haris, an Associate Professor at the University of Pennsylvania have joined its Scientific Advisory Board.

• Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022

  11/28/2022

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) (a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs)  will be presenting at the Emerging Growth Conference on November 30, 2022.

• Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic

  11/18/2022

  The company announced the first phase of the set of in vitro experiments designed to accomplish this validation was successful.

• Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic

  11/10/2022

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)has recently discussed the use of CAR-T therapies in cancer treatment.

• Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 9, 2022

  11/2/2022

  Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) will be presenting at the Emerging Growth Conference on November 9, 2022 (https://emerginggrowth.com/conference/).

• Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space

  10/26/2022

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patents over the last year on multiple ways to improve CAR-T therapies currently being utilized in the treatment of cancers. 

• Regen BioPharma, Inc. Files Provisional Patent on CAR-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer

  10/5/2022

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)  announced today filing of a provisional patent application with the USPTO entitled " Enhancement of T Cell Homing to Tumors Through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion" with the United States Patent and Trademark Office.

• 

  Research Roundup: Regenerative Potential, Long COVID Insights, Immuno-Oncology and More

  9/23/2022

  This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases. 

• Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy

  9/19/2022

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled "Dual Checkpoint Inhibitor Aptamer Based Therapeutics".

• Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy

  9/13/2022

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today initiation of a series of phased experiments to begin the process of moving its CAR-T cell de-differentiation approach through pre-clinical validation.

• Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors

  8/25/2022

  Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today development of a novel immunotherapy for treatment of solid tumors. Current cellular approaches to kill cancer involve administration of a specific type of modified T cell called "chimeric antigen receptor" (CAR) T cell. 

• Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors

  8/11/2022

  Regen BioPharma, Inc. announced the filing with the United States Patent and Trademark Office of a provisional US patent application covering the Company's novel approach for enabling chimeric antigen receptor -T cell-based therapies to kill solid tumors through prevention of a process called "T cell exhaustion".

• Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine

  7/26/2022

  Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), announced today  the filing with the United States Patent and Trademark Office  of a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine. 

• Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio

  3/16/2022

  Regen BioPharma, Inc. has an extensive intellectual property portfolio consisting of granted patents, published applications and pending applications.

• Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies

  3/10/2022

  Regen BioPharma, Inc. announced a program to accelerate the clinical development of its NR2F6 therapies.